论文部分内容阅读
目前,在浅表性膀胱肿瘤的治疗上,复发是难以避免的问题,而膀胱全切除损伤较大,故多采用各种保守治疗法。近年来,应用免疫疗法治疗膀胱肿瘤已有报道,但是应用干扰素治疗此病者少见。作者报道应用干扰素治疗的11例病人并对其疗效进行了观察.本组11例,男性8例,女性3例.所有病例均系反复应用经尿道切除(TuR)和经尿道电灼(TuC)后复发的膀胱肿瘤患者,且既往未接受过手术、化疗或放疗。1例为浸润性移行上皮癌,其余均为直径1cm 以下之表浅性移行上皮癌.作者应用人的类淋巴母细胞干扰素(HLBI),有8例合并应用静脉注射和局部注射,3例仅行局部注射。注射方法为:静注6.0×10~(?)IU/日,局部注射每周2次,6.0—32×10~(?)IU/次,经尿道将干扰素注入肿瘤根部和肿瘤周围的粘膜下组织.
At present, in the treatment of superficial bladder tumors, recurrence is an unavoidable problem, and the total excision of the bladder is relatively large, so many conservative treatments are used. In recent years, the use of immunotherapy to treat bladder tumors has been reported, but the use of interferon to treat this disease is rare. The authors reported 11 patients treated with interferon and observed their efficacy. There were 11 patients in this group, 8 males and 3 females. All cases were treated with repeated transurethral resection (TuR) and transurethral electrocautery (TuC). Patients with recurrent bladder cancer who had not received surgery, chemotherapy, or radiotherapy before. One case was infiltrating transitional epithelial carcinoma, and the rest were superficial transitional epithelial carcinomas with a diameter of 1 cm or less. The authors used human lymphoblastic interferon (HLBI), 8 cases were combined with intravenous injection and local injection, 3 cases. Only local injections. The injection methods were: intravenous injection of 6.0×10 IU/day, local injection twice per week, 6.0-32×10 IU/times, transurethral injection of interferon into the tumor roots and mucosa around the tumor. Under the organization.